BioNTech's ADC Candidate Hits Key Milestone, Paving Way for 2026 FDA Filing

BioNTech SE’s strategic pivot from a pandemic-focused vaccine maker to a fully-fledged oncology company received a significant boost this week. New clinical data for a key cancer drug candidate has analysts reaffirming bullish ratings and sets the stage for a crucial regulatory submission next year.

The company, alongside its partner DualityBio, presented compelling Phase 2 results for its antibody-drug conjugate (ADC) BNT323/DB-1303 at the Society of Gynecologic Oncology’s Annual Meeting in San Juan. The drug candidate is being studied in patients with HER2-expressing, advanced endometrial cancer who have progressed after prior chemotherapy. The data revealed a confirmed objective response rate of 47.9% across all evaluable patients. For the subset of patients who had previously received an immunotherapy checkpoint inhibitor, the response rate was 49.3%.

A deeper analysis showed a striking correlation with the level of HER2 expression. In patients whose tumors exhibited very high HER2 density, the response rate soared to 73.1%. The therapy remained active across lower expression levels, indicating a potentially broad patient population. The median duration of response was 10.3 months, with a median progression-free survival of 8.1 months.

Investors reacted positively to the news, sending BioNTech’s share price up by approximately 6% to €84.25 on Monday. The clinical update also prompted action from Wall Street. Morgan Stanley modestly increased its price target from $125 to $126, maintaining an Overweight rating. Berenberg Bank reiterated its Buy recommendation. According to data from MarketBeat, the average analyst price target for BioNTech stands at $133.13, suggesting substantial upside from current trading levels.

Should investors sell immediately? Or is it worth buying BioNTech?

The safety profile observed in the 145-patient cohort was deemed manageable. Treatment-related adverse events of Grade 3 or higher occurred in 46.9% of participants. Specific lung inflammation events, a known class effect for ADCs that is closely monitored across the industry, were reported in 4.8% of cases. The company stated the profile was consistent with prior experience for this type of therapy.

These results form the foundation for BioNTech’s planned next step: submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration in 2026. The candidate already holds Fast-Track and Breakthrough Therapy designations from the FDA, which could expedite the final review process. A global Phase 3 confirmatory trial is already underway in parallel.

The upcoming year is pivotal for BioNTech’s oncology ambitions. Key milestones for 2026 include not only the BLA filing for BNT323/DB-1303 but also the readout from the ongoing Phase 3 study in endometrial cancer and data presentation from a fully enrolled Phase 3 trial in breast cancer. The company’s broader late-stage pipeline also includes two other Phase 3 candidates, Gotistobart and Pumitamig.

BioNTech at a turning point? This analysis reveals what investors need to know now.

This progress stems from a strategic acquisition. In 2023, BioNTech paid an initial $170 million to partner with DualityBio on this ADC platform, with potential success-based milestones reaching up to $1.5 billion. The latest data validates that investment.

Shareholders will have additional corporate matters to consider soon. The company’s virtual Annual General Meeting is scheduled for May 15, where proposals include expanding the supervisory board and creating new authorized capital of up to €129.5 million. The first-quarter financial results for 2026 are due on May 5.

Ad

BioNTech Stock: New Analysis - 13 April

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECHS | boerse | 69140698 |